# Human leukemia virus related peptides, antibodies of the peptides and a process for production of the antibodies.

## Abstract
An antibody of a human leukemia virus related peptide obtainable by collecting an antibody produced in a mammal body by administering to the mammal an antigen prepared by reacting a human leukemia virus related peptide select ed from the group consisting of a peptide represented by formula 1 R Pro Val Met His Pro His Gly Ala Pro OH wherein R is a hydrogen atom or a group shown by formula, H Tyr a peptide represented by formula 2 H Tyr Val Glu Pro Thr Ala Pro Gln Val Leu OH 2 a peptide represented by formula 3 R Ile Pro His Pro Lys Asn Ser Ile Gly Gly Glu Val OH 3 wherein R is the same as defined above a peptide represented by formula 4 R Thr Trp Thr Pro Lys Asp Lys Thr Lys Val Leu OH 4 wherein R is the same as defined above a peptide represented by formula 5 H Val Val Gln Pro Lys Lys Pro Pro Pro Tyr OH 5 a peptide representedby formula 6 R Met Gly Gln Ile Phe Ser Arg Ser Ala Ser Pro OH 6 wherein R is the same as defined above and a peptide represented by formula 7 H Tyr Pro Glu Gly Thr Pro Lys Asp Pro Ile Leu Arg Ser Leu OH 7 as a hapten, with a carrier in the presence of a hapten carrier binding agent. Also disclosed is the method of ob taining the antibody and specific peptides.

## Claims
CLAIMS 1. An antibody of a human leukemia virus related peptide obtair3ble by collecting an antibody produced in a mammal body by administering to the mammal an antigen prepared by reacting a human leukemia virus related peptide selected from the group consisting of a peptide represented by general formula 1 R Pro Val Met His Pro His Gly Ala Pro OH 1 wherein R is a hydrogen atom or a group shown by general formula, H Tyr a peptide represented by general formula 2 H Tyr Val Glu Pro Thr Ala Pro Gln Val Leu OH 2 a peptide represented by general formula 3 R Ile Pro His Pro Lys Asn Ser Ile Gly Gly Glu Val OH 3 wherein R is the same as defined above a peptide represented by general formula 4 R Thr Trp Thr Pro Lys Asp Lys Thr Lys Val Leu OH 4 wherein R is the same as defined above a peptide represented by general formula 5 H Val Val Gln Pro Lys Lys Pro Pro Pro Tyr OH 5 a peptide represented by general formula 6 R Met Gly Gln Ile Phe Ser Arg Ser Ala Ser Pro OH 6 wherein R is the same as defined above and, a peptide represented by general formula 7 H Tyr Pro Glu Gly Thr Pro Lys Asp Pro Ile Leu Arg Ser Leu OH 7 as a hapten, with a carrier in the presence of a haptencarrier binding agent. 2. The antibody as claimed in Claim 1, wherein said carrier is selected from the group consisting of an animal serum albumin, an animal serum globulin, an animal thyroglobulin, an animal hemoglobulin, an animal hemocyanin, an ascaris extract, a polylysine, a polyglutamic acid, a lysine glutamic acid copolymer, and a copolymer containing lysine or ornithine and said hapten carrier binding agent is selected from the group consisting of a diazonium com pound, an aliphatic dialdehyde, a dimaleimide compound, a maleimidocarboxyl N hydroxysuccinimide ester and a carbodiimide. 3. The antibody as claimed in Claim 2, wherein said mammal is rabbit or guinea pig. 4. The antibody as claimed in Claim 3, wherein said carrier is an ascaris extract, Keyhole limpet hemocyanin or bovine serum albumin and said hapten carrier binding agent is glutaraldehyde, N,N dicyclohexylcarbodiimide or bisdiazotized benzidine. 5. A method for preparing an antibody of a human leukemia virus related peptide comprising reacting a human leukemia virus related peptide selected from the group consisting of a peptide represented by general formula 1 R Pro Val Met His Pro His Gly Ala Pro OH 1 wherein R is a hydrogen atom or a group shown by general formula,. H Tyr a peptide represented by general formula 2 H Tyr Val Glu Pro Thr Ala Pro Gln Val Leu OH 2 a peptide represented by general formula 3 R Ile Pro His Pro Lys Asn Ser Ile Gly Gly Glu Val OH 3 wherein R is the same as defined above a peptide represented by general formula 4 R Thr Trp Thr Pro Lys Asp Lys Thr Lys Val Leu OH 4 wherein R is the same as defined above a peptide represented by general formula 5 H Val Val Gln Pro Lys Lys Pro Pro Pro Tyr OH 5 a peptide represented by general formula 6 R Met Gly Gln Ile Phe Ser Arg Ser Ala Ser Pro OH 6 wherein R is the same as defined above and, a peptide represented by general formula 7 H Tyr Pro Glu GIy Thr Pro Lys Asp Pro Ile Leu Arg Ser Leu OH 7 as a hapten, with a carrier in the presence of a haptencarrier binding agent to form an antigen, administering the resulting antigen to a mammal to form an antibody, and collecting the antibody. 6. A human leukemia virus related peptide selected from the group consisting of a peptide represented by the general formula 1 R Pro Val Met His Pro His Gly Ala Pro OH 1 wherein R is a hydrogen atom or a group of the formula, HTyr in which Tyr moiety may be labelled with radioactive iodine a peptide represented by general formula 2 H Tyr Val Glu Pro Thr Ala Pro Gln Val Leu OH 2 a peptide represented by the general formula 3 R Ile Pro His Pro Lys Asn Ser Ile Gly Gly Glu Val OH 3 wherein is the same as defined above a peptide represented by the general formula 4 R Thr Trp Thr Pro Lys Asp Lys Thr Lys Val Leu OH 4 wherein R is the same as defined above a peptide represented by the formula 5 H Val Val Gln Pro Lys Lys Pro Pro Pro Tyr OH 5 in which Tyr moiety may be labelled with radioactive iodine a peptide represented by the general formula 6 R Met Gly Gln Ile Phe Ser Arg Ser Ala Ser Pro OH 6 wherein R is the same as defined above and, a peptide represented by the formula 7 H Tyr Pro Glu Gly Thr Pro Lys Asp Pro Ile Leu Arg Ser Leu Arg Ser Leu OH 7 in which Tyr moiety may be labelled with radioactive iodine. 7. A peptide according to Claim 6 which is represented by general formula 1 R Pro val Met His Pro His Gly Ala Pro OH 11 wherein R is a hydrogen atom or a group of the formula, HTyr. 8. A peptide according to Claim 6, which is represented by the formula 2 H Tyr Val Glu Pro Thr Ala Pro Gln Val Leu OH 2 9. A peptide according to Claim 6, which is represented by general formula 3 R Ile Pro His Pro Lys Asn Ser Ile Gly Gly Glu Val OH 3 wherein R represents a hydrogen atom or a group of the formula H Tyr. 10. A peptide according to Claim 6, which is represented by general formula 4 R Thr Trp Thr Pro Lys Asp Lys Thr Lys Val Leu OH 4J wherein R represents a hydrogen atom or a group of the formula H Tyr. 11. A peptide according to Claim 6, which is represented by the formula 5 H Val Val Gln Pro Lys Lys Pro Pro Pro Tyr OH 5 12. A peptide according to Claim 1, which is represented by general formula 6 R Met Gly Gln Ile Phe Ser Arg Ser Ala Ser Pro OH 6 wherein R represents a hydrogen atom or a group of the formula H Tyr. 13. A peptide according to Claim 6, which is represented by the formula 7 H Tyr Pro Glu Gly Thr Pro Lys Asp Pro Ile Leu Arg Ser Leu Ou 7 14. A peptide according to Claim 6, which is represented by the formula H Tyr Pro Val Met His Pro His Gly A1a Pro OH wherein Tyr represents Tyr labelled with radioactive iodine. 15. A peptide according to Claim 6, which is represented by the formula H Tyr Val Glu Pro Thr Ala Pro Gln Val Leu OH wherein Tyr represents Tyr labelled with radioactive iodine. 16. A peptide according to Claim 6, which is represented by the formula H Tyr I 1e Pro His Pro Lys Asn Ser I le Gly Gly Glu Val OH wherein Tyr represents Tyr labelled with radioactive iodine. 17. A peptide according to Claim 6, which is represented by the formula H Tyr Th r Trp Thr Pr o Lys Asp Ly s Thr Lys Val Leu OH wherein Tyr represents Tyr labelled with radioactive iodine. 18. A peptide according to Claim 6, which is represented by the formula H Val Val Gln Pro Lys Lys Pro Pro Pro Tyr OH wherein Tyr represents Tyr labelled with radioactive iodine. 19. A peptide according to Claim 6, which is represented by the formula H Tyr Met Gly Gln Ile Phe Ser Arg Ser Ala Ser Pro OH wherein Tyr represents Tyr labelled with radioactive iodine. 20. A peptide according to Claim 6, which is represented by the formula H Tyr Pro Glu Gly Thr Pro Lys Asp Pro Ile Leu Arg Ser Leu OH wherein Tyr represents Tyr labelled with radioactive iodine.

## Description
HUMAN LEUKEMIA VIRUS RELATED PEPTIDES, ANTIBODIES OF THE PEPTIDES AND A PROCESS FOR PRODUCTION OF THE ANTIBODIES The present invention relates to novel peptide associated with human leukemia virus hereafter also referred to as ATLV short for adult T cell leukemia virus or asHTLV short for human T cell leukemia virus and more particularly, to peptides associated with such viral infections as well as mature T cell leukemia or lymphoma such as adultT cell leukemia, cutaneous T cell lymphoma, etc. In the specification, amino acids, peptides, protective groups, active groups, nucleotides and others are expressed pursuant to the IUPAC Rules, the IUB Rules or common symbols established in the art when they are abbreviated examples of which are given below. In case that optical isomers can be present with respect to amino acids or the like, an L form is meant unless otherwise indicated. Ser serine Leu leucine Thr threonine Asn asparagine Gln glutamineGlu glutamic acidLys lysinePro prolineVal valineTrp tryptophaneHis histidineAsp aspartic acidGly glycineIle isoleucineAla alanineTyr tyrosineMet methioninePhe phenylalanineArg arginineCys cysteineA adenine T thymine G guanineC cytosineTos p toluenesulfonyl groupBoc tert butoxycarbonyl groupONP p nitrophenoxy groupBzl benzyl groupOBzl benzyloxy group C12 Bzl 2,6 dichlorobenzyl group C1 Z 2 chlorobenzyloxycarbonyl group Human leukemia virus has been isolated from a patient with adult T cell leukemia ATL and has been shown to be closely associated with the disease. The provirus gene integrated in host cell DNA was molecularly cloned and the complete nucleotide sequence was determined by M. yoshida and H. Sugano, the present inventors. The present invention has been accomplished based on the aforesaid basic information and is directed to such virus related peptides aiming at diagnosis of such virus infections as well as a process for preparation of anc a method of measurement for a specific antibody to these peptides. The nucleotide sequence coding for a precursor of core gag proteins of the thus determined virus gene described above is shown in Table 1 below. Table 1 ATG GGC CAA ATC TTT TCC CGT AGC GCT Met Gly Gln Ile Phe Ser Arg Ser Ala AGC CCT ATT CCG CGA CCG CCC CGG GGG Ser Pro Ile Pro Arg Pro Pro Arg Gly CTG GCC GCT CAT CAC TGG CTT AAC TTC Leu Ala Ala His His Trp Leu Asn Phe CTC CAG GCG GCA TAT CGC CTA GAA CCC Leu Gln Ala Ala Tyr Arg Leu Glu Pro GGT CCC TCC AGT TAC GAT TTC CAC CAGGly Pro Ser Ser Tyr Asp Phe His GlnTTA AAA AAA TTT CTT AAA ATA GCT TTALeu Lys Lys Phe Leu Lys Ile Ala LeuGAA ACA CCG GCT CGG ATC TGT CCC ATTGlu Thr Pro Ala Arg Ile Cys Pro IleAAC TAC TCC CTC CTA GCC AGC CTA CTCAsn Tyr Ser Leu Leu Ala Ser Leu LeuCCA AAA GGA TAC CCC GGC CGG GTG AATPro Lys Gly Tyr Pro Gly Arg Val AsnGAA ATT TTA CAC ATA CTC ATC CAA ACCGlu Ile Leu His Ile Leu Ile Gln ThrCAA GCC CAG ATC CCG TCC CGT CCC GCGGln Ala Gln Ile Pro Ser Arg Pro AlaCCA CCG CCG CCG TCA TCC CCC ACC CACPro Pro Pro Pro Ser Ser Pro Thr HisGAC CCC CCG GAT TCT GAT CCA CAA ATCAsp Pro Pro Asp Ser Asp Pro Gln IleCCC CCT CCC TAT GTT GAG CCT ACG GCCPro Pro Pro Tyr Val Glu Pro Thr AlaCCC CAA GTC CTT CCA GTC ATG CAT CCAPro Gln Val Leu Pro Val Met His ProCAT GGT GCT CCT CCT AAC CAT CGC CCAHis Gly Ala Pro Pro Asn His Arg ProTGG CAA ATG AAA GAC CTA CAG GCC ATTTrp Gln Met Lys Asp Leu Gln Ala IleAAG CAA GAA GTC TCC CAA GCA GCC CCTLys Gln Glu Val Ser Gln Ala Ala ProGGG AGC CCC CAG TTT ATG CAG ACC ATCGly Ser Pro Gln Phe Met Gln Thr IleCGG CTT GCG GTG CAG CAG TTT GAC CCCArg Leu Ala Val Gln Gln Phe Asp ProACT GCC AAA GAC CTC CAA GAC CTC CTGThr Ala Lys Asp Leu Gln Asp Leu Leu CAG TAC CTT TGC TCC TCC CTC GTG GCTGln Tyr Leu Cys Ser Ser Leu Val AlaTCC CTC CAT CAC CAG CAG CTA GAT AGCSer Leu His His Gln Gln Leu Asp SerCTT ATA TCA GAG GCC GAA ACC CGA GGTLeu Ile Ser Glu Ala Glu Thr Arg GlyATT ACA GGT TAT AAC CCA TTA GCC GGTIle Thr Gly Tyr Asn Pro Leu Ala GlyCCC CTC CGT GTC CAA GCC AAC AAT CCAPro Leu Arg Val Gln Ala Asn Asn ProCAA CA CAA GGA TTA AGG CGA GAA TACGln Gln Gln Gly Leu Arg Arg Glu TyrCAG CAA CTC TGG CTC GCC GCC TTC GCCGln Gln Leu Trp Leu Ala Ala Phe AlaGCC CTG CCG GGG AGT GCC AAA GAC CCTAla Leu Pro Gly Ser Ala Lys Asp ProTCC TGG GCC TCT ATC CTC CAA GGC CTGSer Trp Ala Ser Ile Leu Gln Gly LeuGAG GAG CCT TAC CAC GCC TTC GTA GAAGlu Glu Pro Tyr His Ala Phe Val GluCGC CTC AAC ATA GCT CTT GAC AAT GGGArg Leu Asn Ile Ala Leu Asp Asn GlyCTG CCA GAA GGC ACG CCC AAA GAC CCCLeu Pro Glu Gly Thr Pro Lys Asp ProATC TTA CGT TCC TTA GCC TAC TCC AATIle Leu Arg Ser Leu Ala Tyr Ser AsnGCA AAC AAA GAA TGC CAA AAA TTA CTAAla Asn Lys Glu Cys Gln Lys Leu LeuCAG GCC CGA GGA CAC ACT AAT AGC CCTGln Ala Arg Gly His Thr Asn Ser ProCTA GGA GAT ATG TTG CGG GCT TGT CAGLeu Gly Asp Met Leu Arg Ala Cys GlnACC TGG ACC CCC AAA GAC AAA ACC AAAThr Trp Thr Pro Lys Asp Lys Thr Lys GTG TTA GTT GTC CAG CCT AAA AAA CCC Val Leu Val Val Gln Pro Lys Lys Pro CCC CCA AAT CAG CCG TGC TTC CGG TGC Pro Pro Asn Gin Pro Cys Phe Arg Cys GGG AAA GCA GGC CAC TGG AGT CGG GAC Gly Lys Ala Gly His Trp Ser Arg Asp TGC ACT CAG CCT CGT CCC CCC CCC GGG Cys Thr Gln Pro Arg Pro Pro Pro Gly CCA TGC CCC CTA TGT CAA GAC CCA ACT Pro Cys Pro Leu Cys Gln Asp Pro Thr CAC TGG AAG CGA GAC TGC CCC CGC CTA His Trp Lys Arg Asp Cys Pro Arg Leu AAG CCC ACT ATC CCA GAA CCA GAG CCA Lys Pro Thr Ile Pro Glu Pro Glu Pro GAG GAA GAT GCC CTC CTA TTA GAC CTC Glu Glu Asp Ala Leu Leu Leu Asp Leu CCC GCT GAC ATC CCA CAC CCA AAA AAC Pro Ala Asp Ile Pro His Pro Lys Asn TCC ATA GGG GGG GAG GTT Ser Ile Gly Gly Glu Val From Table 1 above, it is shown that the precursor of core proteins is composed of 429 amino acids. In light of the structure of the terminus p 24 previously reported Proc. Natl. Acad. Sci., U.S.A., vol 79, pp. 1291 1294 1982 , it was expected that the precursor would be further cleaved to form core proteins having the termini p 14, p 24 and p 10. Based on the foregoing viewpoint, the present inventors have found specific peptides which can be haptens of proteins core proteins associated with human leukemia virus described above and have accomplished the present invention. That is, the present invention relates to an antibody of a human leukemia virus related peptide obtainable by collecting an antibody produced in a mammal body by administering to the mammal an antigen prepared by reacting a human leukemia virus related peptide selected from the group consisting of a peptide represented by general formula I R Pro 7al Met His Pro His Gly Ala Pro OH 1 wherein R is a hydrogen atom or a group shown by general formula, H Tyr a peptide represented by general formula 2 E Tyr Val Glu Pro Thr Ala Pro Gln Val Leu OH 2 a peptide represented by general formula 3 R Ile Pro His Pro Lys Asn Ser Ile Gly Gly Glu Val OH 3 wherein R is the same as defined above a peptide represented by general formula 4 R Thr Trp Thr Pro Lys Asp Lys Thr Lys Val Leu OH 41 wherein R is the same as defined above a peptide represented by general formula 5 H Val Val Gln Pro Lys Lys Pro Pro Pro Tyr OH 5 a peptide represented by general formula 6 R Met Gly Gln Ile Phe Ser Arg Ser Ala Ser Pro OH 6 wherein R is the same as defined above and, a peptide represented by general formula 7 H Tyr Pro Glu Gly Thr Pro Lys Asp Pro Ile leu Arg Ser Leu OH 7 as a hapten, with a carrier in the presence of a haptencarrier binding agent. The present invention further relates to a process for production of the foregoing antibody. The present invention also relates to human leukemia virus related peptide and a process for production thereof. Fig. 1 is a curve showing the affinity of Peptide A to the antibody of the present invention. Fig. 2 is a curve showing the reactivity specificity of the antibody of the present invention to ATL associated antigen ATLA . Fig. 3 is a curve showing the reactivity specificity of the antibody of the present invention to ATL associated antigen ATLA and to Peptide C. Fig. 4 is a curve showing the reactivity specificity of the antibody of the present invention to ATLassociated antigen ATLA and to Peptide F. Fig. 5 is a curve showing the reactivity specificity of the antibody of the present invention to ATLassociated antigen ATLA and to Peptide H. The peptides of the present invention shown by formulae 1 to 7 described above can all be easily prepared by simple operations utilizing easily accessible, commercially available amino acids. From each of the peptides, antigens can be prepared using them as haptens.From the thus obtained antigens, antibodies having a specific reactivity with virus associated proteins can be obtained. Particularly when the peptides shown by formula 1 are employed, antibodies having a reactivity particular ly with p 24 can be obtained. These specific antibodies are usable for purification of virus associated proteins, by binding these antibodies to carriers for use of, e.g., affinity chromatography, and utilizing the bound antibodies in the chromatography, etc. The specific antibodies can also be utilized as specific antibodies in various immunological measurements of such virus associated proteins.Thus, these antibodies are useful for diagnosis of human leukemia virus infections and further for diagnosis, studies, etc. of mature T ceii leukemia or lymphoma such as adult T cell leukemia, cutaneous T cell lymphoma, etc. as well as diseases related thereto. The peptides of the present invention represented by the general formulae 1 through 7 can be prepared by conventional processes for synthesizing peptides more specifically, using processes as described in Schroder andLuhke, The Peptides, vol. 1 1966 , published by AcademicPress, New York, U.S.A., or Izumiya et al., Synthesis of peptides, 1975 , published by Maruzen Publishing Co., Ltd., for example, an azide process, a chloride process, an acid anhydride process, a mixed anhydride process, a DCC process, an active ester process a p nitrophenyl ester process, anN hydroxysuccinimide ester process, a cyanomethyl ester process, etc. , a process using a Woodward reagent K, a carbodiimidazoie process, an oxidative reduction process, a DCC additive HONB, HOBt, HOSu process, etc. Solid phase and liquid phase syntheses are both applicable to the foregoing processes. The peptides of the present invention are prepared in accordance witn the aforesaid processes for synthesizing ordinary polypeptides, generally either by a so called stepwise process which comprises condensing an amino acid to the terminal amino acid one by one in sequence, or by coupling fragments divided into several groups to the terminal amino acid. In more detail, for example, in case that a solid phase synthesis is adopted, the C terminal amino acid is bound to an insoluble carrier through its carboxyl group.The insoluble carrier is not particularly limited as long as it has a binding capability to a reactive carboxyl group.Examples of such insoluble carriers include halogenomethyl resins such as chloromethyl resin, bromomethyl resin, etc. hydroxymethyl resins, phenol resins, tert alkyloxycarbonylhydrazided resins, etc. After the amino protective group is removed, an amino group protected amino acid is bound in sequence in accordance with the amino acid sequence shown by general formulae 1 through 7 through condensation of its reactive amino group and the reactive carboxyl group, in sequence, to synthesize step by step. After synthesizing the complete sequence, the peptide is split off from the insoluble carrier to produce the protein. In the foregoing process, it is preferred that respective amino acids of histidine, arginine, tyrosine, glutamic acid, threonine, lysine, aspartic acid and serine be protected at the side chain functional groups. These functional groups at the side chain are protected with ordinary protective groups which are split off after completion of the reaction. The functional groups which take part in the reaction are generally activated. These processes are known and reagents used in these processes are also appropriately chosen from known ones. Examples of protective groups for amino groups include a benzyloxycarbonyl, Boc, tert amyloxycarbonyl, isobornyloxycarbonyl, p methoxybenzyloxyearbonyl, C1 Z, adamantyloxycarbonyl, trifluoroacetyl, phthalyl, formyl, o nitrophenylsulfenyl, diphenylphosphinothioyl group, etc. Examples of protective groups for the imino group of histidine include a Tos, Bzl, benzyloxycarbonyl, trityl group, etc. Examples of protective groups for arginine include aTos, nitro, benzyloxycarbonyi group, etc. Examples of protective groups for the hydroxy groups of serine and threonine include a Bzl, tert butyl, acetyl, tetrahydropyranyl group, etc. Examples of protective groups for the hydroxy group of tyrosine include a Bzl, C12 Bzl, benzyloxycarbonyl, acetyl, Tos group, etc. Examples of protective groups for the amino group of lysine include a benzyloxycarbonyl, C1 Z, C12 Bzl, Boc, Tos group, etc. Protection for the carboxyl groups of glutamic acid and aspartic acid includes esterification of the carboxylic acids with benzyl alcohol, methanol, ethanol, tert butanol, etc. Examples of activated carboxyl groups include the corresponding acid chlorides, acid anhydrides or mixed acid anhydrides, azides, active esters esters with pentachlorophenol, p nitrophenol, N hydroxysuccinimide, N hydroxybenzotriazole, N hydroxy 5 norbornene 2,3 dicarboxydiimide, etc. In some cases, the peptide bond forming reaction may also be carried out in the presence of carbodiimide reagents such as dicyclohexylcarbodiimide, carbodiimidazole, etc. or tetraethylpyrophosphine, etc. Hereafter, the preparation of the peptides in accordance with the present invention will be explained more specifically with reference to reaction equations below, as an example. Reaction Equations 1 EMI13.1 tb A SEP SEP Tyr SEP SEP OH SEP a tb SEP 1 tb EMI14.1 tb SEP A SEP SEP Tyr SEP SEP R SEP b tb SEP t SEP 1 tb SEP H SEP SEP Tyr SEP SEP R SEP c tb SEP A Pro OH SEP d tb SEP A SEP SEP Pro SEP SEP Tyr SEP SEP R1 SEP e tb SEP 1 SEP 1Jo tb f tb SEP t tb H Val Val Gln Pro Lys Lys Pro Pro Pro Tyr OH SEP 5 tb wherein A represents a protective for an amino group and R1 represents an insoluble carrier. Of the foregoing, preferred A includes Boc, a benzyloxycarbonyl group, a p methoxybenzyloxycarbonyl group or the like and preferred R1 includes chloromethylated polystyrene or the like, respectively. In case that amino acids used possess functional groups at the side chain thereof which do not participate in each of the reactions, the amino acids are protected by the protective groups described above in a conventional manner and the protective groups are split off at the same time as splitting off of the insoluble carrier R1. In the processes described above, the reaction of the amino acid a with the insoluble carrier R1 b is carried out by utilizing the reactive carboxyl group of the amino acid a and binding it to R1 in a conventional manner. The reaction is effected in an appropriate solvent in the presence of basic compounds, e.g., triethylamine, potassium tert butoxide, cesium carbonate, cesium hydroxide, etc., in the case of using, e.g., chloromethylated polystyrene. Examples of solvents include dimethylformamide DMF , dimethylsulfoxide DMSO , pyridine, chloroform, dioxan, dichloromethane, tetrahydrofuran, N methylpyrrolidone, hexamethylphosphoric acid triamide, etc. or a mixture solvent thereof. The above reaction is generally completed at temperatures of about 0 to about 850C, preferably at 25 to 800C for several minutes to about 24 hours.It is preferred that an amount of the amino acid to the insoluble carrier be set forth such that the former is employed in an excess amount, generally 1 to 3 time equivalents per 1 equivalent of the latter. Splitting of the protective group A for the thus obtained amino acid shown by general formula b is carried out in a conventional manner. For example, there are hydrogenation using catalysts such as palladium, palladium black, etc. a reductive method involving reduction, etc. with metallic sodium in liquid ammonia acidolysis using strong acids such as trifluoroacetic acid, hydrogen chloride, hydrogen fluoride, methanesulfonic acid, hydrogen bromide, etc. The hydrogenation using the foregoing catalysts can be carried out, e.g., under hydrogen pressure of 1 atm at temperatures of O to 400C. It is preferred that the catalyst be used generally in an amount of about 100 mg to about 1 g.The reaction is generally completed within about 1 to about 48 hours. The acidolysis described above is carried out generally at temperatures of about 0 to about 300C, preferably 0 to 200C for about 15 minutes to about 1 hour, in the absence of any solvent. It is preferred that the acid be used in an amount of generally 5 to 10 times that of the raw compound. In case that the protective group A alone is wished to be split off in the acidolysis, it is preferred to use trifluoroacetic acid or hydrogen chloride as the acid.The aforesaid reduction with metallic sodium in liquid ammonia can be carried out generally at temperatures of about 40 to about 700C, using metallic sodium in such an amount that is colored to permanent blue for about 30 seconds to about 10 minutes. The reaction of th subsequently obtained amino acid in a solid phase shown by general formula c and the amino acid d or a derivative thereof in which the carboxyl group is activated is carried out in the presence of a solvent. As solvents, there can be used various known solvents conventionally used in peptide condensation, for example, anhydrous dimethylformamide, dimethylsulfoxide, pyridine, chloroform, dioxan, dichloromethane, tetrahydrofuran, ethyl acetate, N methylpyrrolidone, hexamethylphosphoric acid triamide or a solvent mixture thereof.The reaction can also be conducted, if necessary and desired, in the presence of reagents conventionally employed in ordinary peptide bond forming reactions, for example, dehydrating and condensing agents such as carbodiimides, e.g., N,N dicyclohexylcarbodiimide DCC , N ethyl N dimethylaminocarbodiimide, l ethyl3 diisopropylaminocarbodiimide, l cyclohexyl 3 2 morpholi nyl 4 ethyi carbodiimide, etc. While there is no particular limitation to the proportion of the amino acid c to the amino acid d to be used, it is preferred that the latter be employed in an amount of an equimolar amount to 10 time moles that of the former, preferably from an equimolar amount to 5 time moles. There is no particular limitation to the amount of the dehydrating and condensing agent to be used, either the agent is generally employed preferably in an equimolar amount to that of the amino acid d . The reaction temperature is suitably chosen from a normal range conventionally used for peptide, bond forming reactions, generally from the range of about 40 to about 600C, preferably from the range of about 20 to about 40 C. The reaction time is generally set forth for about several minutes to about 30 hours. The thus obtained peptide shown by general formula e is, after splitting off the protective group A as described above, condensed in sequence with each of the amino acids, A Pro OH, A Pro OH, A Lys OH, A Lys OH, A Pro OH, AGln OH, A Val OH and A Val OH, in accordance with the amino acid sequence shown by general formula 5 or, derivatives thereof wherein the functional groups at the side chain are protected or the carboxyl groups are activated. Thus, the peptide shown by general formula e can be introduced into the peptide represented by general formula f . These condensation and splitting off of the protective group A are carried out in a manner similar to those described above. The thus obtained peptide f can be introduced into the peptide shown by general formula 5 by splitting of the protective group A, splitting off of the protective groups of the amino acid at the side chain thereof and removing the insoluble carrier R1 Here the removal of the protective groups at the side chain functional groups and the insoluble carrier R1 can be carried out in a manner similar to the splitting off of the protective group A in this case, it is preferred to use hydrogen fluoride, or hydrogen bromide as the acid. All of the amino acids used in the aforesaid processes may be those commercially available. The thus produced peptide of the present invention shown by formula 5 can be isolated and purified from the reaction mixture by means of peptide separation, e.g., extraction, distribution, column chromatography, etc. Further, the peptides represented by general formulae 1 to 4 , 6 and 7 can also be prepared in a manner similar to the process described above. The thus obtained peptides of the present invention are utilizable as labelled antigens employed in radioimmunoassay RIA or enzymeimmunoassay EIA , by introducing thereto radioactive substances such as 1251, 1311, etc. various enzyme reagents such as peroxidase POX , chymotripsinogen, procarboxypeptidase, glyceroaldehyde 3 phosphode hydrogenase, amylase, phospholyraser D Nase, P Nase, ss galactosidase, glucose 6 phosphate dehydrogenase, ornithine decarboxylase, etc. The introduction of the above radioactive substance can be effected in a conventional manner.For example, the introduction of radioactive iodine can be carried out by the oxidative iodination method W.M. Hunter and F.C. Greenwood, Nature, 194, 495 1962 , Biochem. J., 89, 144 1963 using chloramine T, etc. The introduction of enzyme reagents can be conducted by known methods such as conventional couplings, e.g., the B.F. Erlanger, et al method Acta Endocrinol. Suppl., 168, 206 1972 , the M.H.Karol et al method Proc. Natl. Acd. Sci. U.S.A., 57, 713 1967 , etc. Hereafter processes for production of antigens using .the peptides of the present invention as haptens will be described in detail. The aforesaid antigens are prepared by using the peptides of the present invention as haptens and reacting the peptides with a suitable carrier in the presence of a hapten carrier binding agent. In this case, natural and synthetic proteins having a high molecular weight which are conventionally employed in the preparation of antigens can be widely employed as carriers to be bound to haptens.Examples of such carriers include albumins of animal sera such as horse serum albumin, bovine serum albumin, rabbit serum albumin, human serum albumin, sheep serum albumin, etc. globulins of animal sera such as horse serum globulin, bovine serum globulin, rabbit serum globulin, human serum globulin, sheep serum globulin, etc. thyroglobulins of animals such as horse thyroglobulin, bovine thyroglobulin, rabbit thyroglobulin, human thyroglobulin, sheep thyrogiobu lin, etc. hemoglobulins of animals such as horse hemoglobulin, bovine hemoglobulin, rabbit hemoglobulin, human hemoglobulin, sheep hemoglobulin, etc. hemocyanins of animals such as Keyhole limpet hemocyanin KLH , etc. proteins extracted from ascaris ascaris extracts, those described inJapanese Patent Application OPI No 16414 81, J.Immun., 111, 260 268 1973 , ibid., 122, 302 308 1979 , ibid., 98, 893 900 1967 and Am. J. Physiol., 199, 575 578 1960 , or purified products thereof polylysine, polyglutamic acid, lysine glutamic acid copolymers, copolymers containing lysine or ornithine, etc. As hapten carrier binding agents, those conventionally employed in the preparation of antigens can be widely employed. Specific examples of these agents include diazonium compounds for cross linking tyrosine, histidine, tryptophane, etc., e.g., bisdiazotized benzidine BDB , bisdiazotized 3,3 dianisidine BDD , etc. aliphatic dialdehydes for cross linking an amino group with an amino group, e.g., glyoxal, malonedialdehyde, glutaraldehyde, succinaldehyde, adipoaldehyde, etc. dimaleimide compounds for cross linking a thiol group with a thiol group, e.g., N,N o phenylenedimaleimide, N,N m phenylenedimaleimide, etc. maleimidocarboxyl N hydroxysuccinimide esters for cross linking an amino group with a thiol group, e.g., metamaleimidobenzoyl N hydroxysuccinimide ester, 4 maleimidometh yl cyclohexane l carboxyl N1 hydtoxysuccinimide ester, etc. agents used in conventional peptide bond forming reactions for amide binding an amino group with a carboxyl group, e.g., dehydrating and condensing agents such as carbodiimides, e.g., N,N dicyclohexylcarbodiimide, N ethylN dimethylaminocarbodiimide, l ethyl 3 diisopropylaminocarbodiimide, l cyclohexyl 3 2 morpholinyl 4 ethyl carbodi imide, etc.As the foregoing hapten carrier binding agent, it is also possible to use diazonium aryl carboxylic acids such as p diazonium phenylacetic acid, etc. with conventional peptide bond forming agents such as the dehydrating and condensing agents described above in combination. The reaction for preparing the antigens described above is carried out in an aqueous solution or a conventional buffer solution having pH of 7 to 10, preferably in a buffer solution having pH of 8 to 9, at temperatures of about 0 to 40 C, preferably around room temperature. The reaction is generally completed within about 1 to about 24 hours, preferably 3 to 5 hours. Representative examples of buffer solutions which can be used in the above process include 0.2M sodium hydroxide 0.2M boric acid 0.2M potassium chloride buffer solution 0.2M sodium carbonate 0.2M boric acid 0.2M potassium chloride O.05M sodium tetraborate 0.2M boric acid 0.05M sodium chloride buffer solution 0.lM dihydrogen potassium phosphate 0.05M sodium tetra borate buffer solution In the above, proportions of the hapten, haptencarrier binding agent and carrier can be appropriately determined but it is preferred that the carrier be employed in an amount of about 1 to about 6 times, preferably about 1 to about 5 times and the hapten carrier binding agent be employed in an amount of about 5 to about 10 times, the weight of the hapten.By the above reaction, the carrier is bound to the hapten via the hapten carrier binding agent to obtain a desired antigen composed of a peptide carrier complex. After completion of the reaction, the thus obtained antigen can easily be isolated and purified by means of a dialysis method, a gel filtration method, a fractionation precipitation method, etc. The thus obtained antigen binds 5 to 60 mols in average of the peptide thereto per 1 mole of a protein and enables to subsequent preparation of an antibody having a high specificity to the antigen. In the case of the peptide shown by general formula 1 , an antigen to which the peptide is bound in an amount of 5 to 20 molls, preferably 8 to 15 molls, in average, per 1 mole of a protein. The preparation of an antibody using the antigen is carried out by administering the aforesaid antigen to mammals to thereby produce a desired antibody in vivo and collecting the antibody. While there is no particular limitation to mammals provided for the preparation of antibodies, it is generally preferred to use rabbits or guinea pigs. In the production of antibodies, a definite amount of the antigen obtained as described above is diluted with a physiological saline solution to a suitable concentration and the resulting dilution is mixed with a complete Freundgs adjuvant to prepare a suspension. The suspension is administered to mammals. For example, the aforesaid suspension is intracutaneously administered 1 to 5 mg time as the amount of the antigen to rabbit. Then the suspension is administered every two weeks over a period of 2 to 10 months, preferably 4 to 6 months to effect immunization.The collection of the antibody is carried out by collecting blood from the immunized animal after the passage of 1 to 2 weeks subsequent to the final administration, centrifuging the blood and isolating serum from the blood. According to this procedure, an antibody having an excellent specificity to the antigen used can be collected and used for assaying human leukemia virusrelated proteins utilizing RIA, EIA, etc. For purposes of explaining the present invention in more detail, preparations of the peptides shown by general formulae 1 to 7 , antigens obtained from the peptides and antibodies will be shown by way of examples but the present invention is not deemed to be limited thereto. Rf values in the respective preparation examples were measured using solvent mixtures described below by means of thin layer chromatography on silica gel. Rf1. . .n butanol acetic acid water 4 1 5 Rf2...n butanol acetic acid pyridine water 15 3 10 12 Preparation of Peptides SYNTHESIS EXAMPLE 1 1 In 14 ml of a DMSO solution of 5.88 milliequivalents of potassium tert butoxide 1.42 g of a Boc Pro OH was dissolved and 5 g of chloromethylated polystyrene resin Protein Research Promotion Foundation was added to the solution. The mixture was reacted at 800C for 30 minutes.After thoroughly washing the resin subsequently with DMSO, 50 acetic acid chloroform and methylene chloride, the resin was dried under reduced pressure to obtain 5.27 g of BocPro resin. A part of the Boc Pro resin was hydrolyzed and subjected to amino acid analysis. The results indicate that the product contained 0.36 mmol of the amino acid g of the resin. 2 After washing 4 g of the Boc Pro resin obtained in 1 above three times with 30 ml of chloroform, the resin was added to 30 ml of a chloroform solution of 50 trifluoroacetic acid TFA and the mixture was reacted at room temperature for 20 minutes. The reaction mixture was washed once with 30 ml of chloroform, 5 times with 30 ml of methylene chloride, 3 times with 30 ml of a methylene chloride solution of 10 triethyl amine and then 6 times with 30 ml of methylene chloride to obtain H Pro resin. To 25 ml of a solution of 0.68 g of Boc Ala OH in methylene chloride the H Pro resin described above was added and 5 ml of a solution of 0.74 g of DCC in methylene chloride was then added to the resulting mixture. The mixture was reacted at room temperature for 2 hours. After washing the resin 6 times with 30 ml of methylene chloride, the resin was added to 25 ml of a methylene chloride solution of 0.68 g of Boc Ala OH and 0.55 g of l hydroxybenzotriazole. Then, 5 ml of a methylene chloride solution of 0.74 g of DCC was added thereto and the resulting mixture was again reacted in a similar manner double coupling .The resin was thoroughly washed with methylene chloride to obtain Boc Ala Pro resin. 3 In a manner similar to 2 described above, destert butoxycarbonylation hereafter simply referred to as des Boc of the Boc Ala Pro resin was conducted and amino acids described below were then condensed in order, each followed by conducting des Boc. Boc Gly OH 0.63 gEMI26.1 1.47 g Boc Pro OH 0.77 gEMI27.1 1.47 g Boc Met OH 0.90 g Boc Val OH 0.78 g Boc Pro OH 0.77 g Thus 2.2 g of H Pro Val Met His Tos Pro His Tos Gly Ala Pro resin. To the thus obtained resin 2 ml of anisole, 25 ml of hydrogen fluoride and 0.5 ml of ethanedithiol were added. After reacting the mixture at 200C for 30 minutes and then at OOC for 30 minutes, a peptide was obtained. Purification of the peptide using Sephadex G 25 manufactured by Pharmacia Co., Ltd. eluting liquid, 108 aqueous acetic acid solution , CM Sephadex C 25 manufactured by Pharmacia Co., Ltd. eluting liquid, 0.1 0.5M aqueous ammonium acetate solution concentration gradient, pH 4 and then HPLC eluting liquid, 0.01 aqueous ammonium acetate solution acetonitrile 70 30 using p Pondapack C 18 manufactured by Waters Co., Ltd. gave 341 mg of H Pro Val Met His Pro His Gly Ala Pro OH hereafter referred to as Peptide A . Rf values Rf 0.03 Rf2 0.27 Elemental Analysis as H Pro Val Met His Pro His Gly Ala Pro OH. CH3CO2H. 5H2O C H N Calcd. 48.38 7.11 16.67 Found 48.12 7.28 16.39 Amino Acid Analysis analyzed with Hitachi 835 Model Amino Acid Analytical Data Gly 1 1.04 Ala 1 1.07 Val 1 0.99 Met 1 1.00 His 2 2.00 Pro 3 2.88 SYNTHESIS EXAMPLE 2 In a manner similar to Synthesis Example 1 2 described above, 1.1 g of the H Pro Val Met His Tos Pro His Tos Gly Ala Pro resin and 1.06 g of Boc Tyr C12 Bzl OH were reacted by double coupling. Then, the removal of the protective groups and the resin was carried out in a manner similar to Synthesis Example 1 3 described above. The system was similarly purified to obtain 183 mg of H Tyr Pro Val Met His Pro His Gly Ala Pro OH thereafter referred to as Peptide B . Rf values Rfl 0.04 Rf 0.29 Elemental Analysis as C51H72I12N14S.CH3COOH .6H2O C H N 8 Calcd. 50.03 6.96 15.40 Found 49.68 7.07 15.92 Amino Acid Analysis analyzed with Hitachi 835 Model Analytical Data Gly 1 1.07 Ala 1 1.02 Val 1 1.04 Met 1 1.02 Tyr 1 1.02 His 2 2.04 Pro 3 2.80 SYNTHESIS EXAMPLE 3 1 In 14 ml of a DMSO solution of 5.88 milliequivalents of potassium tert butoxide 1.54 g of Boc Leu OH was dissolved and 5 g of chloromethylated polystyrene resin ProteinResearch Promotion Foundation was added to the solution.The mixture was reacted at 800C for 30 minutes. After thoroughly washing the resin, in sequence, with DMSO, 50 acetic acid chloroform and methylene chloride, the resin was dried under reduced pressure to obtain 5.06 g of Boc Leu .resin. A part of the Boc Leu resin was hydrolyzed and subjected to amino acid analysis. The results indicate that the product contained 0.30 mmol of the amino acid g of the resin. 2 After washing 2.17 g of the Boc Leu resin obtained in 1 above three times with 30 ml of chloroform, the resin was added to 30 ml of a chloroform solution of 50 trifluoroacetic acid TFA and the mixture was reacted at room temperature for 20 minutes. The reaction mixture was washed once with 30 ml of chloroform, 5 times with 30 ml of methylene chloride, 3 times with 30 ml of a methylene chloride solution of 10 triethyl amine and then 6 times with 30 ml of methylene chloride to obtain H Leu resin. To 25 ml of a solution of 0.35 g of Boc Val OH in methylene chloride the H Leu resin described above was added and 5 ml of a solution of 0.33 g of DCC in methylene chloride was then added to the resulting mixture. The mixture was reacted at room temperature for 2 hours. After washing the resin 6 times with 30 ml of methylene chloride, the resin was added to 25 ml of a methylene chloride solution of 0.35 g of Boc Val OH and Q.55 g of 1 hydroxybenzotriazole. Then, 5 ml of a methylene chloride solution of 0.33 g of DCC was added thereto and the resulting mixture was again reacted in a similar manner double coupling . The resin was thoroughly washed with methylene chloride to obtain Boc Val Leu resin. 3 In a manner similar to 2 described above des Boc of the Boc Val Leu resin was conducted and amino acids described below were then condensed in order, each followed by conducting des Boc. Boc Gln ONP 0.59 g Boc Pro OB 0.35 g Boc Ala OH 0.31 g Boc Thr Bzl OH 0.50 g Boc Pro OH 0.35 g Boc Glu OBzl OH 0.55 g Boc Val OH 0.35 g Boc Tyr C12 Bzl OH 0.71 g Thus 2.65 g of H Tyr C12 Bzl Val Glu OBzl Pro Thr Bzl Ala Pro Gln Val Leu resin, 1.35 g of which was dissolved in 3 ml of anisole and 30 ml of hydrogen fluoride.After reacting the mixture at 200C for 30 minutes and then at OOC for 30 minutes, hydrogen fluoride was removed by distillation. The residue was extracted with 10 acetic acid and the extract was washed with ether. The aqueous layer was freeze dried and then purified by gel filtration using Sephadex G 10 manufactured by Pharmacia Co., Ltd. eluting liquid, 10 aqueous acetic acid solution , partition chromatography using Sephadex G 25 manufactured by Pharmacia Co., Ltd. eluting liquid, BuOH AcOH H2O 4 1 5 and further with LH 20 manufactured by Pharmacia Co., Ltd. eluting liquid, 1 1000 N HCl to obtain H Tyr Val Glu Pro Thr Ala Pro Gln Val Leu OH hereafter referred to as Peptide C f, Rf values Rfl 0.12 Rf2 0.58 Elemental Analysis as C52H81O16N11.7H2O C H N Calcd. 50.27 7.71 12.40 Found 50.41 7.83 12.41 Amino Acid Analysis analyzed with Hitachi 835 Model Analytical Data Ala 1 1.01Gl 1 Glu 1 EMI32.1 2.09 Leu 1 0.99Pro 2 2.04Thr 1 1.04Tyr 1 0.98 Val 2 1.84 Detected as Glu SYNTHESIS EXAMPLE 4 Each of amino acids described below were condensed, in sequence, with 1.70 g of the Boc Val resin 0.296 mmol g resin obtained in a manner similar to Synthesis Example 3 1 followed by des Boc. Boc Glu OBzl OH 0.43 g Boc Gly OH 0.22 g Boc Gly OH 0.22 g Boc Ile OH 1 2H2o 0.31 g Boc Ser Bzl OH 0.38 g Boc Asn ONP 0.46 g Boc Lys Cl Z OH 0.53 g Boc Pro OH 0.28 g Boc His Tos OH 0.52 g Boc Pro OH 0.28 g Boc Ile OH 1 2H2O 0.31 g Thus 2.25 g of H Ile Pro His Tos Pro Lys Cl Z Asn Ser Bzl Ile Gly Gly Glu OBzl Val resin was obtained, 0.81 g of which was mixed with 15 ml of hydrogen fluoride and 1.5 ml of anisole. The mixture was reacted at 200C for 30 minutes and then at OOC for 30 minutes. After removing an excess of hydrogen fluoride by distillation, the residue was extracted with 10 acetic acid. After washing the extract with ether, the system was freeze dried. Then, purification was conducted by gel filtration with Sephadex G 25 1M acetic acid and then using CM Cellulose 23 manufactured byWhatmann Co., Ltd., 0.04M AcONH4, pH 7.2 to obtain H IlePro His Pro Lys Asn Ser Ile Gly Gly Glu Val OH hereafter referred to as Peptide D . Rf values Rfl 0.01 Rf2 0.42 Elemental Analysis as C55H90O17N16 . 8H2O C H N Calcd. 47.47 7.68 16.10 Found 47.39 7.71 15.98 Amino Acid Analysis analyzed with Hitachi 835 Model Analytical Data Asn 1 0.90 Gly 2 1.99 His 1 1.02 Ile 2 2.02 Lys 1 1.01 Pro 2 1.99 Ser 1 0.91 Val 1 1.01 Glu 1 1.02 Detected as Asp SYNTHESIS EXAMPLE 5 In a manner similar to Synthesis Example 3 2 , 0.19 g of Boc Tyr C12 Bzl OH was reacted with 0.77 g of H IlePro His Tos Pro Lys Cl Z Asn Ser Bzl Ile Gly Gly Glu OBzl Val resin obtained in the same manner as in SynthesisExample 4 by double coupling.Then, the Boc group was split off with TFA to obtain 0.82 g of H Tyr C12 Bzl Ile Pro His Tos Pro Lys Cl Z Asn Ser Bzl Ile Gly Gly Glu OBzl Val resin. The thus obtained resin was mixed with 15 ml of hydrogen fluoride and 1.5 ml of anisole. The mixture was reacted at 200C for 30 minutes and then at OOC for 30 minutes. After removing an excess of hydrogen fluoride by distillation, the residue was extracted with 10 acetic acid. After washing the extract with ether, the system was freeze dried. Then, purification was conducted by gel filtration with Sephadex G 25 1M acetic acid and then usingCM Sephadex G 25 0.04M AcONH4, pH 7.2 to obtain H TyrIle Pro His Pro Lys Asn Ser Ile Gly Gly Glu Val OH hereafter referred to as Peptide E . Rf values Rfl 0.02 Rf2 0.47 Elemental Analysis as C64H99O19N17.8H2O C H N Calcd. 49.44 7.46 15.32 Found 49.43 7.56 15.06 Amino Acid Analysis analyzed with Hitachi 835 Model Analytical Data Asn 1 0.89 Gly 2 1.99 Glu 1 1.02 His 1 1.02 Ile 2 2.04 Lys 1 1.02 Pro 2 2.32 Ser 1 0.91 Val 1 1.01 Tyr 1 1.05 Detected as Asp SYNTHESIS EXAMPLE 6 In a manner similar to Synthesis Example 3 1 , BocLeu resin was prepared. Each of amino acids shown below was reacted, in sequence, with 2.17 g of the thus obtained resin by double coupling in a manner similar to Synthesis Example 3 2 and 3 described above. The des Boc reaction of theTrpcontaining peptide was carried out in the presence of ethanedithiol. Boc Val OH 0.35 g Boc Lys Cl Z OH 0.66 g Boc Thr Bzl OH 0.50 g Boc Lys Cl Z OH 0.66 g Boc Asp OBzl OH 0.52 g Boc Lys Cl Z OH 0.66 g Boc Pro OH 0.35 g Boc Thr Bzl OH 0.50 g Boc Trp OH 0.49 g Boc Thr Bzl OH 0.50 g Thus 3.01 g of H Thr Bzl Trp Thr Bzl Pro Lys ClZ Asp OBzl Lys Cl Z Thr Bzl Lys Cl Z Val Leu resin was obtained. In 15 ml of hydrogen fluoride, 1.5 ml of anisole and 0.8 ml of ethanedithiol 1.10 g of the thus obtained resin was dissolved. The solution was reacted at 200C for 30 minutes and then at OOC for 30 minutes. After removing an excess of hydrogen fluoride by distillation, the residue was extracted with 10 acetic acid. After washing the extract with ether, the system was freeze dried.Then, purification was conducted by gel filtration with SephadexG 25 1M acetic acid , CM Cellulose 23 0.05M AcONH4, pH 7.2 and LH 20 10 3 NHC1 to obtain H Thr Trp Thr Pro Lys Asp Lys Thr Lys Val Leu OH hereafter referred to as Peptide F . Rf values Rfl 0.01 Rf2 0.44 Elemental Analysis as C81H101O17N15.17H2O C H N Calcd. 45.15 8.39 12.95 Found 45.12 8.65 12.89 Amino Acid Analysis analyzed with Hitachi 835 Model Analytical Data Asp 1 0.91 Lys 3 3.20 Leu 1 1.00 Pro 1 1.00 Thr 3 2.89 Trp 1 0.93 Val 1 0.98 SYNTHESIS EXAMPLE 7 Boc Tyr C12 Bzl OH, 0.13 g, was reacted with 0.55 g of H Thr Bzl Trp Thr Bzl Pro Lys Cl Z Asp OBzl Lys Cl Z Thr Bzl Lys Cl Z Val Leu resin by double coupling.Then the Boc group was split off with TFA in the presence of ethanedithiol to obtain 0.59 g of H Thr C12 Bzl Trp Thr Bzl Pto Lys Cl Z Asp OBzl Lys Cl Z Thr BzI Lys CI Z Val Leu resin. The thus obtained resin was dissolved in 15 ml of hydrogen fluoride, 1.5 ml of anisole and 0.8 ml of ethanedithiol. The solution was reacted at 200C for 30 minutes and then at OOC for 30 minutes. After removing an excess of hydrogen fluoride by distillation, the residue was extracted with 10 acetic acid. After washing the extract with ether, the system was freeze dried. Then, purification was conducted with CM Cellulose 23 0.05M AcONH4, pH 7.2 and LH20 10 NHC1 to obtain H Tyr Thr Trp Thr Pro Lys Asp LysThr Lys Val Leu OH hereafter referred to as Peptide G . Rf values Rfl 0.01 Rf2 0.47 Elemental Analysis as C70H110O19N16.l7H2O C H N Calcd. 47.08 8.13 12.55 Found 46.89 8.34 12.54 Amino Acid Analysis analyzed with Hitachi 835 Model Analytical Data Asp 1 0.91 Lys 3 3.10 Leu 1 1.02 Pro 1 1.20 Thr 3 2.85 Trp 1 0.92 Val 1 0.93 SYNTHESIS EXAMPLE 8 1 In 42 ml of a DMSO solution of 15.33 milliequivalents of potassium tert butoxide 7.53 g of Boc Tyr C12 Bzl OH was dissolved and 10 g of chloromethylated polystyrene resin Protein Research Promotion Foundation was added to the solution. The mixture was reacted at 800C for 30 minutes.After thoroughly washing the resin, in sequence, with DMSOr 50 acetic acid chloroform and methylene chloride, the resin was dried under reduced pressure to obtain 12 g of Boc Tyr Cl2 Bzl resin. A part of the thus obtained resin was hydrolyzed and subjected to amino acid analysis. The results indicate that the product contained 0.31 mmol of the amino acid g of the resin. 2 After washing 1.70 g of the Boc Tyr C12 Bzl resin obtained in 1 above three times with 30 ml of chloroform, the resin was added to 30 ml of a chloroform solution of 50 trifluoroacetic acid TFA and the mixture was reacted at room temperature for 20 minutes. The reaction mixture was washed once with 30 ml of chloroform, 5 times with 30 ml of methylene chloride, 3 times with 30 ml of a methylene chloride solution of 108 triethyl amine and then 6 times with 30 ml of methylene chloride to obtain H Tyr cl2 Bzl resin. To 25 ml of a solution of 0.28 g of Boc Pro OH in methylene chloride the H Tyr C12 Bzl resin described above was added and 5 ml of a solution of 0.27 g of DCC in methylene chloride was then added to the resulting mixture. The mixture was reacted at room temperature for 2 hours. After washing the resin 6 times with 30 ml of methylene chloride, the resin was added to 25 ml of a methylene chloride solution of 0.28 g of Boc Pro OH and 0.55 g of l hydroxybenzotriazole. Then, 5 ml of a methylene chloride solution of 0.27 g of DCC was added thereto and the resulting mixture was again reacted in a similar manner double coupling .The resin was thoroughly washed with methylene chloride to obtain Boc Pro Tyr C12 Bzl resin. 3 In a manner similar to 2 described above, des Boc of the Boc Pro Tyr C12 Bzl resin was conducted. Then, amino acids, amino acids wherein functional groups at the side chain thereof were protected or carboxyl groups were activated, described below were condensed in order, followed by conducting des Boc. Boc Pro OH 0.28 g Boc Pro OH 0.28 g Boc Lys C1 Z OH 0.55 g Boc Lys Cl Z OH 0.55 g Boc Pro OH 0.28 g Boc Gln ONP 0.48 g Boc Val OH 0.29 g Boc Val OR 0.29 g Thus 2.57 g of H Val Val Gln Pro Lys C1 Z Lys C1 Z Pro Pro Pro Tyr Cl2 Bzl resin. The thus obtained resin, 1.20 g, was dissolved in 2 ml of anisole and 20 ml of hydrogen fluoride. The solution was incubated at 200C for 30 minutes and then at 00C for 30 minutes. Thereafter an excess of hydrogen fluoride was removed by distillation.The residue was extracted with 10 acetic acid and the extract was washed with ether. The aqueous layer was freeze dried and then purified by gel filtration using Sephadex G25 manufactured by Pharmacia Co., Ltd. eluting liquid, lM acetic acid and further using CM 23 Cellulose manufactured by Whatmann Co., Ltd. eluting liquid, 0.04M ammonium acetate pH 7.2 to obtain 162 mg of H Val Val Gln ProLys Lys Pro Pro Pro Tyr OH. hereafter referred to as Peptide H 1. Rf values Rfl 0.01 Rf2 0.27 Elemental Analysis as C56H89013N13 .3CH3Co2H.4H2O C J H 8 N Calcd. 53.02 7.82 12.96 Found 52.94 8.06 12.74 Amino acid analysis analyzed with Hitachi 835 Model Analytical Data Gln 1 1.05 Lys 2 2.17 Pro 4 4.02 Tyr 1 1.05 Val 2 1.69 Detected as Glu SYNTHESIS EXAMPLE 9 In a manner similar to Synthesis Example 8 l , BocPro resin 0.44 mmol g resin was prepared. Each of amino acids or derivatives thereof shown below was reacted, in sequence, with 1.20 g of the thus obtained resin by double coupling in a manner similar to Synthesis Example 8 2 and 3 described above. The des Boc reaction was then carried out. Boc Ser Bzl OH 0.39 g Boc Ala OH 0.25 g Boc Ser Bzl OH 0.39 g Boc Arg Tos OH 0.56 g Boc Ser Bzl OH 0.39 g Boc Phe OH 0.35 g Boc Ile OH 1 2H20 0.32 g Boc Gln ONP 0.49 g Boc Gly OH 0.23 g Boc Met OH 0.33 g Thus 1.58 g of H Met Gly Gln Ile Phe Ser Bzl Arg Tos Ser Bzl Ala Ser Bzl Pro resin was obtained. In 10 ml of hydrogen fluoride, 0.5 ml of 1,2 ethanedithiol and 1 ml of anisole 0.40 g of the thus obtained resin was dissolved. The solution was incubated at 200C for 30 minutes and then at OOC for 30 minutes. After removing an excess of hydrogen fluoride by distillation under reduced pressure, the residue was extracted with 10 acetic acid. After washing the extract with ether1 the system was freeze dried. Then1 purification was conducted by gel filtration with Sephadex G 25 manufactured by Pharmacia Co., Ltd. eluting liquid, 1M acetic acid and CM Cellulose 23 manufactured by Whatmann Co., Ltd. 0.1 to 0.5M ammonium ace tate, pH 5.0, linear concentration gradient to obtain 32 mg of H Met Gly Gln Ile Phe Ser Arg Ser Ala Ser Pro OH hereafter referred to as Peptide I . Rf values Rfl 0.01 Rf2 0.50 Elemental Analysis as C50H8lOl6Nl5S .CH3CO2H.5H2O C H N Calcd. 46.94 7.20 15.79 Found 47.01 7.32 15.66 Amino acid analysis analyzed with Hitachi 835 Model Analytical Data Ala t1 1.07 Arg 1 1.07 Gln 1 1.00 Gly 1 1.00 Ile 1 0.91 Met 1 0.94 Phe 1 0.93 Pro 1 1.07 Ser 3 2.98 Detected as Glu SYNTHESIS EXAMPLE 10 In a manner similar to Synthesis Example 8 2 described above, 0.47 g of Boc Tyr C12 Bzl OH was reacted with 0.41 g of H Met Gly Gln Ile Phe Ser Bzl Arg Tos Ser Bzl Ala Ser Bzl Pro resin by double coupling.Then, theBoc group was split off with trifluoroacetic acid to obtain H Tyr Cl2 Bzl Met Gly Gln Ile Phe Ser Bzl Arg Tos Ser Bzl Ala Ser Bzl Pro resin. The thus obtained resin was mixed with 10 ml of hydrogen fluoride, 1 ml of anisole and 0.5 ml of 1,2 ethanedithiol. The mixture was incubated at 200C for 30 minutes and then at OOC for 30 minutes. After removing an excess of hydrogen fluoride by distillation under reduced pressure, the residue was extracted with 10 acetic acid. After washing the extract with ether, the system was freeze dried.Then, purification was conducted by gel filtration with Sephadex G 25 manufactured byPharmacia Co., Ltd., 1M acetic acid and then by HPLC using a debelogil column manufactured by Chemco Co., Ltd. eluting liquid, 0.lM NaH2PO4 acetonitrile 80 20 . Thereafter, the purified matter was desalted with Sephadex G 25 manufactured by Pharmacia Co., Ltd. eluting liquid, lM acetic acid to obtain 9.23 mg of H Tyr Met Gly Gln Ile PheSer Arg Ser Ala Ser Pro OH hereafter referred to as Peptide J1 . Rf values Rf 0.01 Rf2 0.52 Elemental Analysis as C59Hg0018NlrS CH3C02H.6B20 C 8 E N Calcd. 48.47 7.07 14.82 Found 48.63 7.01 14.77 Amino acid analysis analyzed with Hitachi 835 Model Analytical Data Ala 1 1.03 Met 1 1.00 Arg 1 1.07 Phe 1 1.09 Gln 1 1.03 Pro 1 0.99 Gly 1 1.14 Ser 3 2.68 Ile 1 1.03 Tyr 1 1.03 Detected as Glu SYNTHESIS EXAMPLE 11 In a manner similar to Example 8 l , 0.27 mmol g resin of Boc Leu resin was prepared. Each of amino acids or derivatives thereof described below were reacted, in sequence, with 2 g of the Boc Leu resin by double coupling in a manner similar to Synthesis Example 6 2 and 3 .Then des Boc reaction followed. Boc Ser OH 0.40 g Boc Arg Tos OH 0.58 g Boc Leu OH.H2O 0.34 g Boc Ile OH.1 2H2O 0.32 g Boc Pro OH 0.29 g Boc Asp OBzl OH 0.44 g Boc Lys Cl Z OH 0.56 g Boc Pro OH 0.29 g Boc Thr Bzl OH 0.39 g Boc Gly OH 0.24 g Boc Glu OBzl OH 0.46 g Boc Pro OH 0.29 g Boc Tyr C12 Bzl OH 0.57 g Thus 2.62 g of Boc Tyr C12 Bzl Pro Glu OBzl Gly Thr Bzl Pro Lys Cl Z Asp OBzl Pro Ile Leu Arg Tos Ser Leu resin was obtained. In 20 ml of hydrogen fluoride and 2 ml of anisole 1.62 g of the thus obtained resin was dissolved. The solution was reacted at 200C for 30 minutes and then at OOC for 30 minutes. After removing an excess of hydrogen fluoride by distillation under reduced pressure, the residue was extracted with 10 acetic acid. After washing the extract with ether, the system was freeze dried.Then, the extract with ether, the system was freeze dried.Then, purification was conducted by gel filtration withSephadex G 25 1M acetic acid and then HPLC using debelogil column eluting liquid, 0.1M phosphite buffer acetonitrile 80 20 to obtain 104 mg of a peptide, H Tyr Pro Glu GlyThr Pro Lys Asp Pro Ile Leu Arg Ser Leu OH hereafter referred to as Peptide K . Rf values Rfl 0.01 Rf2 0.42 Elemental Analysis as C72H116O22N18.CH3CO2H.7H2O C H N z Calcd. 50.16 7.62 14.23 Found 49.87 7.60 14.29 Amino acid analysis analyzed with Hitachi 835 Model Analytical Data Asp 1 0.96 Lys 1 1.13 Arg 1 1.02 Pro 3t 2.79 Glu 1 1.05 Ser 1 0.92 Gly 1 1.03 Thr 1 0.99 Ile 1 0.99 Tyr 1 0.97 Leu 2 2.11 SYNTHESIS EXAMPLE 12 The same procedures as in Synthesis Example 11 were repeated except that 0.58 g of Boc Ser Bzl OH was used in place of 0.40 g of Boc Ser OH to obtain 120 mg of Peptide K having the same physical properties as above. Preparation of Antigen PREPARATION EXAMPLE 1 To 3.0 ml of a 0.05M phosphate buffer pH 7.0 5 mg of Peptide A obtained in Synthesis Example 1 and 25 mg of a protein extracted from the ascaris ASC were added and 0.2 ml of a 2 glutaraldehyde GA solution was dropwise added to the resulting solution. The mixture was stirred at room temperature for 3 hours. Thereafter the reaction mixture was dialized at 40C with distilled water overnight.After freeze drying, 29 mg of an immune antigen was obtained. The antigen is hereafter referred to as Antigen A . Antigen A bound 10 mols in average of Peptide A per 1 mol of the ascaris when an average molecular weight was made 100,000 the same is true hereinafter . This binding rate of Peptide A to the ascaris was determined as follows A fraction of Peptide A bound to the ascaris was separated from another fraction of other product dimer of Peptide A by gel filtration of Antigen A obtained with Sephadex G 50 eluting liquid, physiological saline solution . detection,OD 280 nm eluting rate, 3 ml hour fractionated amount, 1 ml each a calibration curve of a peptide dimer having standard concentrations was prepared to determine the amount of the aforesaid dimer and the thus determined amount of the dimer was subtracted from the amount of Peptide A used as a raw material, assuming that the thus subtracted amount would be all bound to the ascaris since neither the unreacted ascaris nor Peptide A was recognized. Such is hereafter the same also in the following examples for preparing antigens. PREPARATION EXAMPLE 2 To 3.0 ml of a 0.05M phosphate buffer pH 7.0 5 mg of Peptide A obtained in Synthesis Example 1 and 25 mg of a protein extracted from the ascaris were added and 200 mg of dicyclohexylcarbodiimide DCC was dropwise added to the resulting solution. The mixture was stirred at room temperature for 3 hours. Thereafter the reaction mixture was dialized at 40C with distilled water overnight. After freeze drying, 28 mg of an immune antigen was obtained. The antigen is hereafter referred to as Antigen B . Antigen B bound thereto 12 mols of Peptide A per 1 mol of the ascaris in average. PREPARATION EXAMPLE 3 An immune antigen was obtained in a manner similar to Preparation Example 1 described above except that KLH Sigma Co., Ltd. was used instead o the protein extracted from the ascaris. Hereafter the antigen is referred to as Antigen C . Antigen C bound thereto 10 mols of Peptide A per 1 mol of KLH in average when an average molecular weight was made 100,000 the same is true hereinafter . PREPARATION EXAMPLE 4 An immune antigen was obtained in a manner similar to Preparation Example 2 described above except that KLH Sigma Co., Ltd. was used instead of the protein extracted from the ascaris. Hereafter the antigen is referred to as Antigen D . Antigen D bound thereto 9 mols of Peptide A per 1 mol of KLH in average. PREPARATION EXAMPLE 5 An immune antigen was obtained in a manner similar to Preparation Example 2 described above except that BSA andPeptide B were used instead of the protein extracted from the ascaris and Peptide A, respectively. Hereafter the antigen is referred to as Antigen E . Antigen E bound thereto 15 mols of Peptide B per 1 mol of BSA in average. PREPARATION EXAMPLE 6 To 3.0 ml of a 0.05M phosphate buffer pH 7.0 5 mg of Peptide C obtained in Synthesis Example 3 and 12 mg ofKLH Sigma Co., Ltd. were added and 0.2 ml of a 2 glutaraldehyde solution was dropwise added to the resulting solution. The mixture was stirred at room temperature for 3 hours. Thereafter the reaction mixture was dialized at 40C with distilled water overnight. After freeze drying, 16.5 mg of the desired antigen was obtained. The antigen is hereafter referred to as Antigen F . Antigen F bound thereto 10 mols of Peptide C per 1 mol of KLH when an average molecular weight was made 100,000 in average. PREPARATION EXAMPLE 7 1 A BDB solution was prepared by adding 83.25 mg of benzidine to a solvent mixture of 20 ml of 0.2N BC1 and 3 ml of DMF, stirring the mixture under ice cooling, gradually adding 2 ml of distilled water containing 87.03 mg of sodium nitrite to the solution and then stirring the mixture for 30 minutes. 2 In 1 ml of a 0.16M borate buffer pH 9.0 containing 0.13M NaCl were dissolved 5.08 mg of Peptide G and 8.07 mg of KLH. The solution was slowly stirred at 40C. To the solution 1 ml of the BDB solution obtained in 1 above was gradually added dropwise. The reaction solution was adjusted with 0.5N NaOH to pH 9.0 followed by reacting for further 2 hours at 4aC. Thereafter the reaction mixture was dialized at 40C with distilled water overnight. After freeze drying, 12.27 mg of the desired antigen was obtained. Hereafter the antigen is referred to as Antigen G . Antigen G bound thereto 35 mols of Peptide G per 1 mol of KLH in average.. PREPARATION EXAMPLE 8 In a manner similar to Preparation Example 7 described above, 12.74 mg of the desired antigen was obtained except for using 5.17 mg of Peptide E and 8.03 mg of KLH.Hereafter the antigen is referred to as Antigen H . Anti gen H bound thereto 42 mols of Peptide E per 1 mol of KLH in average. PREPARATION EXAMPLE 9 Following the preparation examples described above, immune antigens shown in Table 2 below were obtained. Table 2 Molar Ratio of Binding Carrier Hapten Antigen Hapten Carrier Agent Bond mg mg mg I Peptide C ASC GA 1 24 3 6 0.59 J Peptide G ASC BDB 1 14 2 4 0.75 K Peptide C ASC BDB 1 18 3 6 1.50 L Peptide D ASC DCC 1 25 3 6 0.67 M Peptide E ASC BDB 1 22 3 6 1.19 N Peptide F ASC DCC 1 16 3 6 0.50 PREPARATION EXAMPLE 10 To 3.0 ml of a 0.05M phosphate buffer pH 7.0 5.09 mg of Peptide I obtained in Synthesis Example 9 and 25.10 mg of KLH were added and 0.2 ml of a 2 glutaraldehyde solution was dropwise added to the resulting solution. The mixture was stirred at room temperature for 3 hours. Thereafter the reaction mixture was dialized at 40C with distilled water overnight. After freeze drying, 26.49 mg of the desired antigen was obtained.The antigen is hereafter referred to as Antigen O . Antigen 0 bound thereto 10 mols of Peptide I per 1 mol of KLH when an average molecular weight was made 100,000 in average. PREPARATION EXAMPLE 11 1 A BDB solution was prepared by adding 83.25 mg of benzidine to a solvent mixture of 20 ml of 0.2N HC1 and 3 ml of DMF, stirring the mixture under ice cooling, gradually adding 2 ml of distilled water containing 87.03 mg of sodium nitrite to the solution and then stirring the mixture for 30 minutes. 2 In 1 ml of a 0.16M borate buffer pH 9.0 containing 0.13M NaCl were dissolved 5.13 mg of Peptide K and 8.10 mg of KLH. The solution was slowly stirred at 40C. To the solution 1 ml of the BDB solution obtained in 1 above was gradually added dropwise. The reaction solution was adjusted with 0.5N NaOH to pH 9.0 followed by reacting for further 2 hours at 40C. Thereafter the reaction mixture was dialized at 40C with distilled water overnight. After freeze drying, 12.76 mg of the desired antigen was obtained.Hereafter the antigen is referred to as Antigen P . Anti gen P bound thereto 18 mols of Peptide K per 1 mol of KLH in average. PREPARATION EXAMPLE 12 In a manner similar to Preparation Example 11 described above, 12.74 mg of the desired antigen was obtained except for using 5.17 mg of Peptide H and 8.03 mg of KLH.Hereafter the antigen is referred to as Antigen Q . Antigen Q bound thereto 25 mols of Peptide H per 1 mol of KLH in average. PREPARATION EXAMPLE 13 Following the preparation examples described above, immune antigens shown in Table 3 below were obtained. Table 3 Molar Ratio of Binding Carrier Hapten Antigen Hapten Carrier Anent Bond mg mg mg R Peptide I ASC GA I 19 2 4 0.37 S Peptide I ASC DCC 1 21 2 4 0.70 T Peptide K ASC DCC 1 17 2 4 0.57 U Peptide K ASC GA 1 14 2 4 0.30 V Peptide K ASC BDB 1 13 2 4 0.69 W Peptide H ASC BDB 1 19 5 10 2.42 X Peptide J BSA DCC 1 22 3 6 0.40 Preparation of Antibody PREPARATION EXAMPLE 1 1 After dissolving 100 vg of Antigen A obtained inPreparation Example of Antigen 1 in 1.5 ml of a physiological saline solution, respectively, 1.5 ml of a freund s adjuvant was added to the solution to obtain a suspension. The suspension was subcutaneously administered to 3 rabbits 2.5 to 3.0 kg . The suspension was given at the same dose 9 times every 2 weeks.After the final administration, blood was collected from the test animals.Anti sera ATLA antibodies of the present invention were obtained by centrifugation. The antibodies are referred toAntibody A, Antibody B and Antibody C, respectively, to each of the rabbits. 2 In a manner similar to Preparation Example of Antibody 1 1 above, ATLA antibodies of the present invention were obtained from 6 rabbits 2.5 to 3.0 kg except thatAntigen B obtained in Preparation Example of Antigen 2 described above was employed. The antibodies are referred to as Antibody D, Antibody E, Antibody F, Antibody G, Antibody H and Antibody I, respectively, to each of the rabbits. 3 In a similar manner to Preparation Example of Antibody I 1 above, ATLA antibodies were obtained except that Antigen C, Antigen D and Antigen E obtained in PreparationExamples of Antigen 3, 4 and 5, respectively, were employed. The thus obtained antibodies are referred to as Antibody J, Antibody K and Antibody L, respectively. PREPARATION EXAMPLE 2 After dissolving 100 vg of each of Antigens F, G andH obtained in Preparation Examples of Antigen 6 to 8 in 1.5 ml of a physiological saline solution, respectively, 1.5 ml of a Freund s adjuvant was added to each of the solutions to obtain suspensions. Each of the suspensions was subcutaneously administered to several rabbits New Zealand white rabbits , respectively. Each of the suspensions was given at the same dose 6 times every 2 weeks and then at the same dose as the initial dose 3 times monthly. Seven days after the final administration, blood was collected from the test animals. Anti sera were obtained by centrifugation and the desired antibodies were obtained, respectively.Antibodies are referred to as follows Antibody M which was obtained from Antigen F, Antibody N , Antibody O , Antibody P , Antibody Q and Antibody R from Antigen G Antibody S , Antibody T , Antibody U , Antibody V and Antibody W from Antigen H. PREPARATION EXAMPLE 3 Using each 500 Vg of the antigens obtained in Preparation Example 9 of Antigen described above, antibodies shown in Table 4 below were obtained, respectively, in a manner similar to Preparation Example 2 of Antibody described above. Table 4 Antigen No. Antibody No. Antigen I Antibody X Y Z Antigen J Antibody AA AB AC Antigen K Antibody AD AE AF Antigen L Antibody AG Antigen M Antibody AH Al AJ Antigen N Antibody AK PREPARATION EXAMPLE 4 After dissolving 100 g of each of Antigens O, P and Q obtained in Preparation Examples of Antigen 10 to 12 in 1.5 ml of a physiological saline solution, respectively, 1.5 ml of a Freund s adjuvant was added to each of the solutions to obtain suspensions. Each of the suspensions was subcutaneously administered to several rabbits New Zealand white rabbits 2.5 to 3.0 kg , respectively. Each of the suspensions was given to the rabbits at the same dose level 6 times every 2 weeks and then at the same dose as the initial dose 3 times monthly. Seven days after the final administration, blood was collected from the test animals.Anti sera were obtained by centrifugation and the desired antibodies were obtained, respectively. Antibodies are referred to as follows Antibody AL which was obtained from Antigen O Antibody AM , Antibody AN , Antibody AO , Antibody AP and Antibody AQ from Antigen P and Antibody AR from antigen Q. PREPARATION EXAMPLE 5 Using each 500 vg of the antigens obtained in Preparation Example 13 of Antigen described above, antibodies shown in Table 5 below were obtained, respectively, in a manner similar to Preparation Example 4 of Antibody de scribed above. Table 5 Antigen No. Antibody No. Antigen R Antibody AS AT Antigen S Antibody AU AV Antigen T Antibody AW AX Antigen U Antibody AY AZ Antigen V Antibody BA BB Antigen W Antibody BC t BD BE BF BG Antigen X Antibody BH PREPARATION EXAMPLE 6 Using 500 pg of Antigen A prepared in SynthesisExample 1 of antigen described above, an antibody was obtained in a manner similar to Preparation Example 1 ofAntibody described above. This antibody is referred to asAnibody BI.Preparation of Labelled Peptide PREPARATION EXAMPLE 1 Peptide B obtained in Synthesis Example 2 was label led in accordance with the method using chloramin T as follows That is, 20 pl of a 0.5M phosphate buffer containing 1 mCi of Na 125I carrier free N.E.N. was added to 10 p1 of a 0.5M phosphate buffer pH 7.5 containing 5 pg of the aforesaid peptide and then 20 pl of a 0.5M phosphate buffer containing 20 pl of chloramin T was added thereto. After stirring the mixture for 25 seconds at room temperature, 20 u1 of a 0.5M phosphate buffer containing 100 pg of sodium metabisulfite Na2S205 was added to the mixture to complete the reaction.Then, 10 p1 of a cold 10 aqueous sodium iodide solution was added to the reaction mixture. The reaction mixture was passed through a Sephadex G 25 column 1.0 to 50 cm eluting liquid, a 0.2M ammonium acetate buffer containing 0.1 BSA and 0.01 NaN3 pH 5.5 to obtainPeptide B labelled with 1251. The radioactivity qf the thus labelled peptide was 255 pCi pg, which is referred to as Labelled Peptide B . PREPARATION EXAMPLE 2 In a manner similar to Preparation Example 1 ofLabelled Peptide described above, each of peptides labelled with 125 were obtained, respectively, except that Peptide C, Peptide E, Peptide G, Peptide H, Peptide J andPeptide K were employed in lieu of Peptide B, respectively.The radioactivity of each of the peptides was not lower than 1000 pCi pg. Measurement of Titer The titer of each of the antibodies obtained as described above was measured as follows That is, each of the antibodies was diluted with a physiological saline solution to 10, 102, 103, 104, 105, .....,. times, respectively.To 100 p1 each of the thus obtained dilations, were added 0.1 ml of a labelled peptide diluted to about 9500 cpm in the case of Antibodies A to L,Labelled Peptide B was employed Labelled Peptide C in the case of Antibodies M, X to Z, AD to AF Labelled Peptide E in the case of Antibodies S to W and AG to AJ LabelledPeptide G in the case of Antibodies N to R, AA to AC and AK Labelled Peptide H in the case of Antibodies AR and BC toBG Labelled Peptide J in the case of Antibodies AL, AS toAV and BH and Labelled Peptide K in the case of AntibodiesAM to AQ and AW to BB, respectively and 0.2 ml of a 0.05M phosphate buffer pH 7.4 containing 0.25 BSA, 10 mM EDTA and 0.02 NaN3 . The mixture was incubated at 40C for 24 hours.The resulting antibody 125 I labelled peptide complex was separated from the unreacted unbound 125I labelled peptide by the dextran activated charcoal method and the centrifugal method 40C, 30 minutes, 3000 rpm and the radioactive ray was counted to measure a binding rate of the antibody to the 125I labelled peptide at each of the dilution concentrations. The binding rate of the antibody to the labelled peptide is taken on the vertical axis and the dilution magnification of the antibody is taken on the abscissa. At each of the concentrations, the binding rate is plotted. Then, the dilution magnification of the antibody where the binding rate shows 50 , i.e., a titer of the antibody, is determined. The results obtained are shown in Table 6 below. Table 6 Antibody No. Titer A 50000 B 1000 C 1500 D 30000 E 2500 F 20000 G 3000 H 15000 I 5000 J 6000 R 3000 L 8000 M 5000 N 250 0 1500 P 32000 Q 3400 R 5000 S 4200 T 720 U 1800 V 420 W 750 X 62500 Y 16500 Z 2300AA 7500AB 18500AC 1800AD 11750AE 2500AF 3250AG 3000AH 19000 AI 2500AJ 9000AK 3500AL 1000 AM 1500 AN 50 AO 5000 AP 2500 AQ 1000 AR 7500 AS 780 AT 2550 AU 15000 AV 2700 AW 175 AX 125 AY 1000 AZ 2650 BA 5250 BB 6000 BC 2100 BD 675 BE 9500 BF 70000 BG 550 BH 10000 BI 6000Test for ATLA Specificity of Antibody 1 Peptide A having various concentrations and ATLA samples described below were employed as samples.ATLA Positive Sample To 5 x 109 of cultured cells of ATLA positive cell line YAM Science, 217, pp. 737 739 1982 j 30 ml of a phys iological saline solution was added followed by homo genization. Then the mixture was centrifuged 105000 x g for 1 hour to collect the supernatant. The amount of the proteins in the supernatant was adjusted with PBS to 10 mg ml the amount of the proteins was mea sured by a coloration method using a reagent for total protein assay made by the Otsuka Assay Research Labora tories, Tonein TP hereafter the supernatant is referred to as YAM Supernatant .ATLA Negative Sample Supernatants obtained by treating CCRF CEM Immunol. Commun., 9 8 , pp. 731 734 1980 and BALL 1 Nature, London, 267, pp. 843 844 1977 which were ATLA negative cell lines in a manner similar to above were employed these supernatants are hereafter referred to as CEM Supernatant and BAL Supernatant , respective ly . Further, a 0.05M phosphate buffer pE 7.4 containing 0.25 BSA, 5mM EDTA and 0.02 NaN3 was employed as a standard diluting solution. In each of test tubes, 0.2 ml of the standard diluting solution, 0.1 ml of a sample, 0.1 ml of Antibody A obtained in Preparation Example of Antibody 1 diluted so as to give a titer of 50,000 in finally obtained assay system and 0.1 ml of 125I labelled peptide a dilution obtained by diluting Labelled Peptide B obtained as described above to about 10000 cpm were charged. After incubating the mixture at 40C for 72 hours, 0.1 ml of normal porcine serum was added thereto. Then, 0.5 ml of a suspension of activated charcoal coated with dextran was added to the mixture. The mixture was allowed to stand for 30 minutes at 40C. Thereafter, the mixture was centrifuged at 40C for 30 minutes at 3000 rpm to separate the antibody 125I labelled peptide complex B from the unreacted unbound 125I labelled peptide F . The radioactive ray of the complex was counted to determine a percentage of B at each concentration and dilution of the respective samples. The results obtained are shown in Fig. 1 and Fig. 2. In each of the figures, the vertical axis represents a binding B Bo x 100 wherein Bo is a percentage of B when the concentration of a sample is made 0 and the abscissa represents concentrations of samples concentration of Peptide A and, protein contents of YAM Supernatant, CEMSupernatant and BALL Supernatant . In Fig. 1, Curve a represents Peptide A. In Fig. 2, Curves b , c and d represent YAM Supernatant, CEM Supernatant and BALL Supernatant, respectively. It is evident that Fig. 1 shows a high degree of the affinity of Antibody A to Peptide A and Fig. 2 shows a high selectivity of the antibody to ATLA. It is further evident from Fig. 2 that no cross to ATLA negative cell induced proteins was observed with the antibodies of the present invention. 2 In a manner similar to 1 above, ATLA specificity test was carried out. The results obtained are shown inFigs. 3 to 5. In the figures, the vertical axis represents a binding B Bo x 100 wherein Bo is a percentage of B when the concentration of a sample is made 0 and the abscissa represents concentrations of th sample concentration of PeptideC, F or H and, protein contents of YAM Supernatant . Fig. 3 shows results of ATLA specificity test usingAntibody X curves a and b represent Peptide C and TAMSupernatant, respectively. Fig. 4 shows results of ATLA specificity test usingAntibody AA curves a and b represent Peptide F and YAMSupernatant, respectively. Fig. 5 shows results of ATLA specificity test usingAntibody BF curves a and b represent Peptide H and YAMSupernatant, respectively. From these figures ATLA specificity of the antibody of the present invention can be seen.